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Background: Soy protein with isoflavones appears to have an adverse effect on thyroid function, but
it is not known whether it is the protein or isoflavone component that is deleterious. The effect of
isoflavone-free soy on thyroid function was determined in patients with subclinical hypothyroidism,
with a secondary aim of assessing its effect on cardiovascular risk indices.
Methods: This was a randomized, double-blind, crossover study involving 80 patients with subclinical
(compensated) hypothyroidism. Patients were randomly assigned to either isolated soy (isoflavone-free)
protein (SP) or casein protein (CP) supplementation for 8 weeks, washed out for 8 weeks, and then
crossed over for a further 8-week period.
Results: Thyroid function was unaffected by either a SP or CP. There were significant decreases in
fasting glucose (4.76 0.6 vs 5.56 1.4, P, 0.01), insulin resistance (3.36 3.0 vs 3.86 3.4, P = 0.05), total
cholesterol (4.4 6 0.9 vs 5.3 6 1.2, P , 0.01), triglycerides (0.9 6 0.5 vs 1.7 6 0.9, P , 0.1), and highly
sensitive C-reactive protein (hsCRP; 0.86 0.7 vs 2.66 2.8, P, 0.01) in the SP group compared with the
CP group. Blood pressure, low-density lipoprotein, and high-density lipoprotein remained unchanged in
both groups.
Conclusion: SP alone had no effect on thyroid function in patients with subclinical hypothyroidism and
resulted in a significant reduction in fasting glucose, insulin resistance, total cholesterol, triglycerides,
and hsCRP compared with CP.
Copyright © 2017 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Soy foods have become popular in Western countries through the suggestion that they have
health benefits, including protection against coronary heart disease [1–3], breast and
prostate cancer [4–6], osteoporosis [7], and alleviation of hot flushes [8]. This has led to the
development of isoflavone supplements and the fortification of foods with soy constituents
[9, 10]. There are concerns that soy may adversely affect thyroid function in susceptible
individuals [11, 12], and in vitro studies have demonstrated that isoflavones inhibit thyroid
Abbreviations: BMI, body mass index; CP, casein protein; fT4, free T4; HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment of insulin resistance; hsCRP, highly sensitive C-reactive protein; LDL, low-density lipoprotein; SP, soy (isoflavone-free)
protein; T3, triiodothyronine; T4, thyroxine; TSH, thyrotropin.
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peroxidase, an enzyme involved in the synthesis of triiodothyronine (T3) and thyroxine (T4)
[13, 14].
The two main components of soy thought to be responsible for most of the proposed health
benefits of soy are soy protein and the soy isoflavones, of which genistein is more biologically
potent that daidzein and glycitein. It is unclear which component of soy (the protein, the
isoflavones, or an interaction between the two)may have an effect on thyroid function [12–15].
It has not previously been possible to determine the relative effective contribution of each
component, as there are no studies either in vitro or in vivo with an isoflavone-free soy
preparation.
Studies have shown that soy protein with isoflavones has an adverse effect on thyroid
function [16, 17], and another study in subclinical hypothyroidism was associated with a
threefold increased risk of developing overt hypothyroidism [15]. These studies have also
highlighted the positive effect of soy on cardiovascular risk, reducing insulin resistance,
highly sensitive C-reactive protein (hsCRP), and blood pressure. However, it is not known
whether the effects observed were due to isoflavones alone or due to the isoflavones in
combination with the soy protein, although a study performed with isoflavones alone showed
no beneficial effects, whereas the same isoflavone preparation with soy protein was effective
in improving glycemic control and reducing cardiovascular risk parameters [18], suggesting
that soy protein alonemay have inherent activity. Therefore, this double-blind, crossover trial
was undertaken to determine the effect of soy protein alone on thyroid parameters in patients
with compromised thyroid function (subclinical hypothyroidism), with a secondary outcome to
evaluate cardiovascular riskmarkers, by comparing 30 g isolated soy (isoflavone-free) protein
(SP) with 30 g casein protein (CP).
1. Subjects and Methods
Eighty patients, 27males and 53 female subjects with subclinical hypothyroidism (age range,
20 to 81 years) [thyrotropin (TSH) value between 5 and 15mU/L; normal range 0.5 to 4.7mU/L,
with a normal free T4 (fT4)], were recruited by identification from the routine biochemical
testing performed at Hull Royal Infirmary, United Kingdom, over a 12-month period. The
screening thyroid function tests were done 4 to 8 weeks after the initial biochemical testing
(Table 1). Exclusion criteria included patients taking thyroxine or drugs that may interfere
with thyroid function, antihypertensive agents, insulin-sensitizing agents, lipid-lowering
medications, as well as antibiotic use within the last 6 months. Women who were contem-
plating pregnancywere also excluded. Subjects were instructed, at randomization and then at
each subsequent visit, to maintain their level of physical activity throughout the study and
avoid food products containing soy, alcohol, vitamin or mineral supplementation, and over-
the-counter medications. Ethics approval was obtained from Hull and East Yorkshire Ethics
Committee.
Forty patients were initiated after randomizationwith a cereal bar containing 30 g isolated
SP and 40 patients with a cereal bar containing 30 g CP per day for 8 weeks (first phase). After
an 8-week washout period, the participants received the alternative supplementation for
Table 1. Thyroid Function Tests at the Start and 2 Months After Supplementation
Soy Protein (SP) Casein Protein (CP) Postactive–Postplacebo
Baseline 8 Weeks P Value Baseline 8 Weeks P Value P Value
fT3 4.44 6 0.51 4.37 6 0.46 0.32 4.40 6 0.58 4.43 6 0.42 0.70 0.88
fT4 12.60 6 1.26 11.06 6 1.63 0.08 12.11 6 1.40 11.93 6 1.77 0.48 0.32
TSH 5.70 6 1.01 5.86 6 2.08 0.56 5.93 6 2.16 5.71 6 2.16 0.12 0.54
fT3, pmol/L; fT4, pmol/L; TSH, mU/L (mean 6 standard deviation).
Abbreviation: fT3, free triiodothyronine.
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8 weeks (second phase). An eight-week time period was chosen for each arm as this was the
minimum time of exposure that might have been expected to affect thyroid function, given
that the half-life of thyroxine is ~7 days. Compliance was calculated by counting the returned
bars.
Soy was supplied by Solbar Industries (Ashdod, Israel). Isoflavones were removed by serial
alcohol washing (Dishman, Ahmedabad, India) to a level ˂300 parts per billion (assayed by
FERA, Sand Hutton, United Kingdom). Casein bars were prepared from a single batch, and
each bar contained the same amount of protein. Soy and casein bars were prepared by Halo
Foods (Swindon, United Kingdom), and the study product was then randomized by Essential
Nutrition (Brough, United Kingdom) using a computer-generated block randomization list.
The primary outcome of the study was a change in serum-free thyroxine, whereas sec-
ondary outcome measures were blood pressure, homeostasis model assessment of insulin
resistance (HOMA-IR), lipids, and hsCRP. Overt hypothyroidism was defined as a combi-
nation of TSH .4.7 mU/L and fT4 ,9 pmol/L. A flow chart of patients through the study is
given in Fig. 1.
A. Study Measurements
The weight and blood pressure of participants were measured, and blood samples were
collected at the beginning and end of each phase, following an overnight fast. Blood pressure
was measured after the patients had been seated quietly for at least 5 minutes with the right
arm supported at heart level. Blood pressure measurements were performed using an au-
tomated device (NPB-3900; Nellcor PuritanBennett, Pleasanton, CA) during each study visit.
Two readings were obtained at the beginning of each visit at least 1 minute apart, and
the mean value was taken. Fasting venous blood samples were collected and separated by
centrifugation at 2000g for 15 minutes at 4°C, and the aliquots were stored at 280°C within
Figure 1. Flow chart describing the progress of patients through the trial.
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1 hour of collection. Plasma glucose was measured using a Synchron LX20 analyzer
(Beckman-Coulter, High Wycombe, United Kingdom), and serum insulin was assayed
using a competitive chemiluminescent immunoassay performed using the DPC Immulite
2000 analyzer (Euro/DPC, Llanberis, United Kingdom). The coefficient of variation of this
methodwas8%, calculatedusingduplicate studysamples.Theanalytical sensitivitywas2mU/mL.
Insulin resistance was calculated using HOMA-IR (insulin 3 glucose)/22.5) [19]. Total
cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol levels weremeasured
enzymatically using a Synchron LX20 analyzer (Beckman-Coulter). Low-density lipoprotein
(LDL) cholesterol was calculated using the Friedewald equation. All thyroid assays were
performed on an Abbott Architect i4000 immunoassay analyzer (Abbott Diagnostics Division,
Maidenhead, United Kingdom). The reference range for TSH was 0.5 to 4.7 mU/L; fT4, 9 to
24 pmol/L; and free T3, 2.5 to 5.3 pmol/L. Urinary iodine measurements in 24-hour urine
collections were undertaken by inductively coupled plasma–mass spectrometry to monitor
for iodine repletion, and plasma phytoestrogen measurement was undertaken by liquid
chromatography–tandem mass spectrometry (HFL Sport Science Laboratory, Cambridge,
United Kingdom).
B. Statistical Analysis
For a significant reduction in fT4, a sample size of 40 patients in a crossover design was
calculated giving 80% power to detect a mean decrease of 0.4 pmol/L fT4, with a two-sided a
error of 0.05 [18]. Given the high dropout rate with this type of study, it was elected to recruit
80 patients and accept a dropout rate of 50%.Mean percentage changes obtained at the end of
supplementation with 30 g SP were compared with the results at the end of placebo CP using
the paired Student t test for biochemical data and Wilcoxon’s signed–rank test for clinical
observations. Baseline parameters were not compared statistically because this was a ran-
domized controlled study [20, 21].
Wilcoxon’s signed–rank test was applied to biochemical data that violated the assumptions
of normality when tested using the Kolmogorov–Smirnov test. The period and the carryover
effect that may have occurred from the crossover design were also tested using the appro-
priate Student t test. Intention to treat analysis was done. Statistical correction for multiple
testing sincewas not done because it can severely reduce power to detect important effects due
to the fact that the general null hypothesis (that all the null hypotheses are true) is not of
interest and there is a high probability of type II errors [22].
Statistical analysis was performed using SPSS for windows version 22.0. An arbitrary level
of 5% statistical significance (two-tailed) was assumed. The data are reported as mean 6
standard deviation.
2. Results
Mean age of patients was 55.16 14.2 years. Themean bodymass index (BMI) of patients was
28.8 6 5.9 kg/m2; mean systolic blood pressure was 134.2 6 22.2 mm Hg; and mean diastolic
blood pressure was 81.56 14.2 mmHg. Thyroid peroxidase antibodies were positive (.75 U/
mL) in 27 (33.7%) patients. Compliance was 98% in both groups. Of the 27male and 53 female
subjects with subclinical hypothyroidism that started the study, 16 males and 26 females
completed.
The mean TSH, free T3, and fT4 levels remained unchanged before and after supple-
mentation with either soy protein or CP. No patient developed overt hypothyroidism during
the study.
Weight and BMI were unchanged after either SP or CP supplementation. There were no
differences in mean systolic or diastolic blood pressures between the groups. There was a
significant decrease in mean glucose (P, 0.01) that reflected in a decrease in HOMA-IR (P =
0.05) in patients who received SP supplementation compared with CP (Table 2).
There was a decrease in the total cholesterol and triglycerides (P , 0.01) in patients who
received SP supplementation compared with CP between groups, but HDL cholesterol levels
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did not differ (Table 2). There was a reduction in LDL of ~3%with soy protein and an increase
in LDL of ~3% with CP; this was not found to be statistically significant (Table 2).
There was a significant reduction in mean hsCRP (P , 0.01) in patients who received SP
that was not seen with CP (Table 2).
The calculated 10-year cardiovascular risk using the Framingham equation was 13.3% for
both SP and CP that fell to 11.2% following SP, a significant 2.1% absolute and a 10% relative
fall (P , 0.05) between groups.
3. Discussion
Studies on soy with isoflavones have shown a significant effect on both T4 and TSH levels [16,
17], and these data using an isolated soy protein, isoflavone-free preparation confirm that SP
is not responsible for those changes that are therefore likely to be due to the intrinsic iso-
flavone component of soy. CP has been shown previously to have no effect on thyroid function
in postmenopausal women [23].
A significant improvement in plasma glucose and a fall inHOMAafter SPwere observed, in
accordance with a meta-analysis of randomized trials [24], and more recent soy isoflavone
studies [16, 17] showed a significant decrease in plasma glucose thatmay in part be due to the
SP alone, as shown in this work.
Insulin resistance (HOMA-IR) significantly improved in patients supplemented with SP
compared with CP, which was in accordance with studies that have shown isoflavones in soy
protein improve insulin resistance [18, 25]; however, this effect appears to be lost when
isoflavones are given alone (without soy protein) [26–28].
There was a significant improvement in total cholesterol and triglyceride values after
soy protein supplementation, although LDL and HDL were not altered. Some previous
studies have suggested that the lipid-lowering effects are mainly due to the isoflavone
content, but this study showed that soy protein alone most likely contributes to the lipid-
lowering effects reported. However, the observed effects on lipid lowering have not been
consistent; some studies have shown an improvement with the soy preparation [29–32],
whereas others have shown no benefit on total cholesterol, LDL cholesterol, and tri-
glycerides [33–35]; likewise, isoflavones alone have shown no lipid benefit [36, 37]. These
differences reported by others may be due in part to the differing preparations used.
Table 2. Subjects’ Characteristics and Effects on Cardiovascular Risk at the Start of the Trial and 2
Months After Supplementation
Soy Protein (SP) Casein Protein (CP) Postactive–Postplacebo
Baseline 8 Weeks PValue Baseline 8 Weeks PValue P Value
Weight 84.0 6 20.4 84.4 6 20.4 0.09 84.4 6 20.3 84.8 6 20.5 0.1 0.99
BMI 29.0 6 5.6 29.1 6 5.7 0.07 29.3 6 5.6 29.4 6 6.1 0.07 0.91
SBP 131.46 18.2 130.36 17.9 0.5 133.56 23.4 129.96 17.8 0.1 0.40
DBP 81.3 6 13.9 78.6 6 13.9 0.2 82.1 6 13.1 77.4 6 11.6 0.01 0.47
Glucose 6.2 6 0.9 4.7 6 0.6 ,0.01 5.4 6 1.3 5.5 6 1.4 0.07 ,0.01
Insulin 12.4 6 9.9 14.9 6 13.6 0.03 13.4 6 10.3 14.3 6 10.5 0.3 0.23
HOMA-IR 3.6 6 3.0 3.3 6 3.0 0.2 3.5 6 3.4 3.8 6 3.4 0.2 0.05
TC 5.3 6 1.2 4.4 6 0.9 ,0.01 5.3 6 1.1 5.4 6 1.2 0.2 ,0.01
LDL 3.3 6 1.1 3.2 6 1.1 0.4 3.2 6 1.2 3.3 6 1.0 0.5 0.26
HDL 1.4 6 0.4 1.5 6 1.6 0.5 1.3 6 0.4 1.3 6 0.4 0.7 0.54
TG 2.6 6 0.9 0.9 6 0.5 ,0.01 1.6 6 0.8 1.7 6 0.9 0.3 ,0.01
hsCRP 3.4 6 2.6 0.8 6 0.7 ,0.01 2.4 6 2.5 2.6 6 2.8 0.5 ,0.01
BMI, kg/m2; SBP,mmHg;DBP,mmHg; glucose, plasma glucose,mmol/L; insulin,mIU/mL; TC,mmol/L; TG,mmol/L;
LDL, mmol/L; HDL, mmol/L; hsCRP, mg/L. To convert values for glucose to milligrams per decilitre, divide by 0.056.
To convert values for insulin to picomoles per liter, multiply by 6. To convert values for cholesterol to milligrams per
decilitre, divide by 0.0259. To convert values for triglycerides to milligrams per decilitre, divide by 0.0113.
Abbreviations: DBP, diastolic blood pressure, SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
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There was no improvement seen in BMI and weight, but the marker of inflammation,
hsCRP, was reduced significantly after soy protein supplementation. In accordance with the
lipid data, previous studies have shown an improvement in hsCRP in some [38, 39] but not all
studies [40, 41] that most likely reflects the differing soy preparations and study conditions
used. Our study suggests that isolated soy protein has anti-inflammatory effects.
Although there was no difference in the protein composition between soy with and
without isoflavones following serial alcohol washing and digestion of protein that should
have not differed following ingestion, nonetheless the serial alcohol washing could have
altered the tertiary structure of the protein and removed other components besides
isoflavones.
The study limitations include the increased dropout seen that was mitigated by appro-
priate powering of the study and its crossover design. The number of participants who
completed the study was similar to other studies [15, 42]. Secondly, the ratio of male and
female participants who completed the study did not alter, thus alleviating the effect of
different response of males and females to soy isoflavones reported previously [43]. Although
there was no difference in the protein composition between soy with and without isoflavones
following serial alcohol washing, and digestion of protein should have not differed following
ingestion, nonetheless the serial alcohol washing could have altered the tertiary structure of
the protein and removed other components besides isoflavones.
In conclusion, isolated SP had no effect on thyroid function in patients with subclinical
hypothyroidism and resulted in a significant reduction in fasting glucose, insulin resistance,
total cholesterol, triglycerides, and hsCRP compared with CP.
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